Objective: Studies of dehydroepiandrosterone (DHEA) therapy in older adults suggest sex-specific effects on bone mineral density (BMD) and body composition, but the ability of a single study to reach this conclusion was limited. We evaluated the effects of DHEA on sex hormones, BMD, fat mass and fat-free mass in older women and men enrolled in four similar clinical trials.
| INTRODUC TI ON
The adrenal steroid dehydroepiandrosterone (DHEA) is a prohormone for the synthesis of biologically active androgens and oestrogens. 1 Between the ages of 20 and 60 years, serum DHEA sulphate (DHEAS) levels decline approximately 70%, 2 reflecting the overall decrease in adrenal production of DHEA. The synthesis of androgens and oestrogens from DHEAS becomes increasingly important as gonadal sex hormone production declines with ageing. It has been estimated that DHEAS is the precursor for all oestrogens and androgens in postmenopausal women and 40% in older men. 3 Because age-related decreases in androgens and oestrogens contribute to the loss of bone mineral density (BMD) and muscle mass in older adults, maintaining youthful levels of DHEA may be an effective strategy for attenuating the rates of loss. 4, 5 It has been postulated that DHEA therapy is safer than oestrogen or testosterone (T) therapy. The rationale for this is that DHEAS circulates as an inactive prohormone that is converted to biologically active sex steroids in a tissue-specific, 6 and presumably tissue-appropriate, manner.
Four single-site, double-blinded, randomized controlled trials (RCTs) sponsored by the National Institute on Aging determined the effects of DHEA therapy on BMD [7] [8] [9] [10] and body composition [7] [8] [9] in older adults. Despite methodological consistencies across these studies (eg, age group, 12-month intervention), different conclusions regarding the effects of DHEA on changes in BMD, fat mass (FM) and fat-free mass (FFM; surrogate measure of muscle mass) were reached. Individually, the four RCTs suggested sex-specific effects of DHEA on BMD and body composition, but the ability of a single study to reach this conclusion was limited. Therefore, the data from these four RCTs were pooled to determine whether there are sex differences in the benefits of DHEA therapy on hip and lumbar spine BMD, FM and FFM and the associated changes in steroid hormones.
| MATERIAL S AND ME THODS

| Sources of data
Individual-level data from four RCTs of DHEA therapy in older adult [7] [8] [9] [10] were merged into a central database by investigators at the University of Colorado Anschutz Medical Campus (CU-AMC). 7 Although each of the RCTs included additional outcomes and, in one RCT an additional treatment arm, 8 the focus of the pooled analysis was on the 12-month changes in BMD, body composition, and circulating hormones and growth factors in response to oral DHEA therapy as compared to placebo. The main characteristics of the studies are briefly described below and in Table 1 . Investigators obtained local institutional review board approval for their RCT.
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| Participants
The RCTs included women and men aged 55-85 years, 9 60 years or older 7, 8 or 65-75 years, 10 who were not using sex hormone therapy. Low serum DHEAS concentration was an inclusion criterion in two studies. 
| Tests and procedures
Bone mineral density and body composition were measured, and blood samples collected before and after the 12-month intervention.
Data from interim measurements of study outcomes 7, 9, 10 were not included in the pooled analysis.
Proximal femur (total hip, neck, trochanter and subtrochanter regions) and lumbar spine (L2-L4) BMD were measured by dualenergy x-ray absorptiometry (DXA) using a Lunar DPX-IQ, 
| Data management
A data dictionary was sent to each RCT investigator, and corresponding data files containing individual data for the cases that had been included in intention-to-treat analyses were returned to CU-AMC. Units of measurement were verified, and raw data converted as needed. No substitution rules were applied for missing data. Thus, the number of cases for each outcome varied and is provided in Tables   1-3 and Supporting Information Table S1 . We performed a sensitivity analysis for all outcomes to address the impact of baseline BMD using BMD T-scores from 3 of the 4 RCTs. A variable for normal BMD (T-score >−1.5) or low BMD (T-score ≤−1.5) was created. Due to the few cases of osteoporosis, we collapsed low bone mass and osteoporosis into a single category.
| Statistical analyses
The BMD indicator was first examined as a covariate in all regression models to test group differences adjusting for normal vs low BMD.
Additional analyses tested the possibility of a differential effect of condition on outcomes by baseline BMD, through the inclusion of a statistical interaction term between condition and the BMD indicator. All conclusions drawn from these sensitivity analyses were the same as the primary approach, and there were no significant interactions between condition and BMD indicator. We therefore report the primary analyses only.
All analyses were performed using SAS software (version 9.3; SAS Institute, Inc, Cary, NC, USA). Results are reported as means and standard deviations (SD) or standard error of the mean (SE). To account for multiple comparisons, the alpha level was set at 0.01.
| RE SULTS
| Baseline characteristics
The pooled ITT cases from the four RCTs demonstrated a balanced representation of sex and allocation to treatment arms (P = 0.77; TA B L E 1 Study characteristics 
| Changes in hormones
The absolute and relative changes in sex hormones and IGF-1 pooled across
RCTs are in Table 3 and Supporting Information Table S1 , respectively.
When expressed as absolute change from baseline to 12 months, serum DHEAS increased by 231 µg/dL (6.24 µmol/L) and 269 µg/dL (7.26 µmol/L) in DHEA-treated women and men, respectively (both P < 0.001 vs placebo; Table 3 ). In DHEA-treated women, there were increases in serum T, E 2 and IGF-1 and a decrease in SHBG (all P < 0.001). In DHEA-treated men, there were increases in serum E 2 (P < 0.001) and IGF-1 (P = 0.04) and a decrease in SHBG (P = 0.001).
When expressed as the per cent of change from baseline (Table S1 ), the statistical results were similar to those for absolute changes.
Differences among the RCTs in the hormone responses to DHEA were not statistically compared because there was considerable variability among the RCTs in the responses. For example, serum E 2 was increased in response to DHEA in men in the Mayo, CU-AMC and WUSM RCTs, but not the UCSD RCT.
| Changes in BMD and body composition
In women, DHEA therapy increased or attenuated the decrease in lumbar spine, total hip and subtrochanter BMD when compared with the placebo group (all P < 0.01; Figure 1 ). In contrast, the changes in BMD were not different between DHEA-and placebo-treated men.
In women, there was a nonsignificant increase in FFM (P = 0.02) in response to DHEA when compared with placebo and no change in FM. In men only, there was no change in FFM and a decrease in FM (P = 0.006) in response to DHEA when compared with placebo ( Figure 2 ).
| Adverse events
Different categorization of events across the four trials precluded pooling of these data. In the summaries of adverse events provided in the original trial publications, more cardiovascular events occurred in participants in the DHEA-treated groups in two trials.
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| D ISCUSS I ON
The analysis of pooled data from four similar RCTs provided evidence that DHEA therapy has sex-specific effects on BMD and body composition in older adults. One year of DHEA therapy increased BMD in women, but not men, and decreased FM in men, but not women.
| Effects of DHEA on T, E 2 , SHBG and IGF-1
The sex-specific effects of DHEA on BMD and body composition in older adults may be explained by differences in the hormonal milieu at baseline, the magnitude of change in circulating sex hormones and the specific actions of sex hormones in target tissues. In older women, the loss of gonadal function at an earlier age than in men increases the reliance on prohormones, such as DHEA, for the synthesis of biologically active androgens and oestrogens. 6 DHEAS is the precursor for 100% of circulating androgens and oestrogens in postmenopausal women. 3 However, at the menopause transition, adrenal production of DHEAS is reduced by ~40% of young adult levels and is not sufficient to prevent bone loss or menopause-related changes in body composition in women.
Across the 4 RCTs, the same dose of DHEA resulted in similar absolute increases in DHEAS in women and men. The concomitant decrease in SHBG indicated an increase in the unbound fraction of sex steroids (ie, biologically active). Even when serum DHEAS was restored to youthful levels in women, E 2 and T remained below premenopausal levels. The increase in E 2 in DHEAtreated women was about one-third that of women treated with 
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Decreased ovarian hormone production during menopause disrupts the remodelling of mature bone resulting in increased bone resorption relative to bone formation. 13 Changes in total hip BMD in older DHEA-treated adults were mediated by increased serum oestrogens, as opposed to T or DHEA therapy, per se. 14 The increases in DHEAS, E 2 and T combined with higher bone turnover may explain the more consistent increases in BMD in older DHEA-treated women compared to men. DHEA therapy suppresses bone resorption, 9,14 which is elevated in women after menopause as a result of the decrease in E 2 , but remains relatively stable in middle-aged and older men. 
| Effects of DHEA on BMD
The observed benefit of DHEA therapy on lumbar spine BMD in older women and men combined was driven by the beneficial effects in women (Figure 1 ). The 1.0% increase from baseline in lumbar spine BMD in women on DHEA was less than that found with alendronate (3%-5%; 5 or 10 μg/d), 16 teriparatide (6%-12%; 10-40 μg/d) 17, 18 or abaloparatide (10%; 80 μg/d). 19 Unlike these pharmaceutical trials, the DHEA trials did not target women with osteoporosis, which may have contributed to the modest increases in BMD.
There is limited knowledge regarding the effects of longer duration DHEA therapy on BMD and body composition in older women.
In one trial, 
| Effects of DHEA on body composition
Sex-specific effects of DHEA therapy on body composition included a 0.5 kg increase in FFM in women and a −0.4 kg loss of FM in men.
For comparison, postmenopausal women treated with combined F I G U R E 1 Between-group differences (DHEA minus placebo) in the 12-month changes in lumbar spine, total hip, femoral neck and trochanter BMD. Estimates were adjusted for baseline and site for pooled results. Values are mean ± SE. **P < 0.01; ***P < 0.001 
| Limitations
Despite many similarities among the four RCTs, there were differences. In two studies, 7,10 calcium and vitamin D supplements were provided to all participants but these studies did not have consistently larger increases in BMD. Low serum DHEAS concentration was required for study entry in two studies. 7, 8 Different DXA instruments were used across the studies. Different assay methods likely contributed to the variability in the changes in sex hormones, particularly the immunoassays for T in women and E 2 in men ( Table 3, Table S1 ).Because of these limitations, the statistical approach included adjustment for performance site.
| CON CLUS IONS
The beneficial effects of DHEA therapy on lumbar spine and hip BMD were specific to older women. It is possible that DHEA therapy could be a strategy to attenuate the decline in BMD in postmenopausal F I G U R E 2 Between-group differences (DHEA minus placebo) in the 12-month changes in fat-free mass and fat mass. Estimates were adjusted for baseline and site for pooled results. Values are mean ± SE. *P < 0.05; **P < 0.01 women who do not tolerate other treatments. The beneficial effects of DHEA replacement on body composition are to modestly increase FFM in women and decrease FM in older men, a reversal of the usual age-related trends in muscle and fat mass. Studies are needed to evaluate the effects of long-term DHEA therapy on the musculoskeletal health of older adults, and to characterize the safety profile of this prohormone. org/0000-0003-0075-0023
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